Literature DB >> 35506103

Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.

Daniel P Cook1, Meng Xu2, Victoria L Martucci1, Jeffrey S Annis3, Melinda C Aldrich1, Anna R Hemnes1, Evan L Brittain1.   

Abstract

Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD). Little is known about the prevalence and clinical profiles of patients with COPD-PH. We report the clinical characteristics, hemodynamic profiles, and prognosis in a large population of patients with COPD referred for right heart catheterization (RHC). We extracted data from all patients referred for RHC between 1997 and 2017 in Vanderbilt's deidentified medical record. PH was defined as mean pulmonary artery pressure >20 mmHg. Pre- and postcapillary PH were defined according to contemporary guidelines. COPD was identified using a validated rules-based algorithm requiring international classification of diseases codes relevant to COPD. We identified 6065 patients referred for RHC, of whom 1509 (24.9%) had COPD and 1213 had COPD and PH. Patients with COPD-PH had a higher prevalence of diabetes, atrial fibrillation, and heart failure compared with COPD without PH. Approximately 55% of patients with COPD-PH had elevated left ventricle (LV) filling pressure. Pulmonary function testing data from individuals with COPD-PH revealed subtype differences, with precapillary COPD-PH having lower diffusion capacity of the lungs for carbon monoxide (DLCO) values than the other COPD-PH subtypes. Patients with COPD-PH had significantly increased mortality compared with COPD alone (hazard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.28-2.26) with the highest mortality among the combined pre- and postcapillary COPD-PH subgroup (HR: 2.39; 95% CI: 1.64-3.47). PH is common among patients with COPD referred for RHC. The etiology of PH in patients with COPD is often mixed due to multimorbidity and is associated with high mortality, which may have implications for risk factor management.
© 2021 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.

Entities:  

Keywords:  COPD; hemodynamic phenotyping; survival outcomes

Year:  2022        PMID: 35506103      PMCID: PMC9052979          DOI: 10.1002/pul2.12006

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   2.886


  39 in total

1.  Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance.

Authors:  Jordan D Awerbach; Kathryn A Stackhouse; Joanne Lee; Talal Dahhan; Kishan S Parikh; Richard A Krasuski
Journal:  Respir Med       Date:  2019-03-15       Impact factor: 3.415

2.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

3.  Long-term data from the Swiss pulmonary hypertension registry.

Authors:  Séverine Mueller-Mottet; Hans Stricker; Guido Domenighetti; Guido Domeninghetti; Andrea Azzola; Thomas Geiser; Markus Schwerzmann; Daniel Weilenmann; Otto Schoch; Jean-Marc Fellrath; Thierry Rochat; Frederic Lador; Maurice Beghetti; Laurent Nicod; John-David Aubert; Vladimir Popov; Rudolf Speich; Stephan Keusch; Elisabeth Hasler; Lars C Huber; Peter Grendelmeier; Michael Tamm; Silvia Ulrich
Journal:  Respiration       Date:  2015-01-31       Impact factor: 3.580

4.  Development of a large-scale de-identified DNA biobank to enable personalized medicine.

Authors:  D M Roden; J M Pulley; M A Basford; G R Bernard; E W Clayton; J R Balser; D R Masys
Journal:  Clin Pharmacol Ther       Date:  2008-05-21       Impact factor: 6.875

5.  Patterns of cardiovascular dysfunction in chronic obstructive lung disease.

Authors:  B Burrows; L J Kettel; A H Niden; M Rabinowitz; C F Diener
Journal:  N Engl J Med       Date:  1972-04-27       Impact factor: 91.245

6.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.

Authors:  R Kessler; M Faller; E Weitzenblum; A Chaouat; A Aykut; A Ducoloné; M Ehrhart; M Oswald-Mammosser
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Jørgen Vestbo; Suzanne S Hurd; Alvar G Agustí; Paul W Jones; Claus Vogelmeier; Antonio Anzueto; Peter J Barnes; Leonardo M Fabbri; Fernando J Martinez; Masaharu Nishimura; Robert A Stockley; Don D Sin; Roberto Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

8.  Right and left ventricular dysfunction in patients with severe pulmonary disease.

Authors:  C D Vizza; J P Lynch; L L Ochoa; G Richardson; E P Trulock
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

Review 9.  Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments.

Authors:  James R Klinger
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

10.  Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxemia.

Authors:  Mihoko Doi; Kikuo Nakano; Takehiko Hiramoto; Nobuoki Kohno
Journal:  Respir Med       Date:  2003-08       Impact factor: 3.415

View more
  2 in total

1.  Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Daniel P Cook; Meng Xu; Victoria L Martucci; Jeffrey S Annis; Melinda C Aldrich; Anna R Hemnes; Evan L Brittain
Journal:  Pulm Circ       Date:  2022-01-03       Impact factor: 2.886

2.  Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing.

Authors:  Shelsey W Johnson; Lauren Finlay; Stephen C Mathai; Ronald H Goldstein; Bradley A Maron
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.